Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2003

View Archived Issues

Inex regains 100% ownership of Onco TCS

AD-452 enters phase I testing

CytoGenix begins preclinical trials with antiherpesvirus DNA drug

New enzyme-based cardiovascular risk assessment test launched by the Mayo Clinic

Indan-based anorectic agents developed at Aventis

New antiproliferative pteridinones synthesized by Boehringer Ingelheim researchers

U. of Connecticut researchers describe CB1 modulators for obesity and other uses

Novel 5alpha-reductase inhibitors covered by Jenapharm patent

Antipsychotic optically active iloperidone metabolites patented by Novartis

New series of PDE5 inhibitors in early development at Schering-Plough

Novartis designs series of cathepsin K inhibitors

Entomed and Achillion collaborate on antiviral drug discovery

Insmed begins named-patient program for SomatoKine

Pegasys more effective than interferon in difficult-to-treat hepatitis B

Zadaxin combination therapy demonstrates sustained response in hepatitis B patients

Preliminary phase II results for RDP-58 in ulcerative colitis and Crohn's disease

Long-term treatment with Fosrenol controls phosphate in end-stage renal disease

Insmed's rhIGFBP-3 improves effect of cancer therapies, inhibits tumor growth

AVI BioPharma's NeuGene program advances

Discovery's lung surfactant shows significant antiinflammatory properties

Enema formulation of alicaforsen assessed in new phase II ulcerative colitis trial

FTI-277 inhibits growth and induces apoptosis in drug-resistant multiple myeloma cells

Anticoagulant efficacy of JVT-803 demonstrated in porcine model of hemodialysis

Evidence for potential of SB-277011-A in drug dependence and psychosis

Inflazyme to acquire GlycoDesign

Microbially produced angiogenesis inhibitor discovered by RIKEN

SAR in a series of acyl sulfonamide antiproliferative compounds

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...